Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up [0.03%]
关于ECHELON-2研究5年随访的前线系统性间变性大细胞淋巴瘤患者 Brentuximab vedotin联合化疗治疗亚组分析的更正公告
Eva Domingo-Domènech,Barbara Pro,Tim Illidge et al.
Eva Domingo-Domènech et al.
Published Erratum
Blood cancer journal. 2026 Jan 28;16(1):21. DOI:10.1038/s41408-025-01432-4 2026
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance [0.03%]
NFκB/IL-6/JAK2/STAT信号轴是骨髓纤维化治疗抵抗的关键靶标
Huiqin Bian,Naseema Gangat,Na Shen et al.
Huiqin Bian et al.
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy [0.03%]
一线免疫化疗的滤泡性淋巴瘤患者的无事件生存率的全基因组关联研究
Hervé Ghesquières,Youenn Drouet,Susan L Slager et al.
Hervé Ghesquières et al.
Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as wel...
Matthew S Davids,Stephan Stilgenbauer,Constantine S Tam
Matthew S Davids
In the decade since FDA approval of the first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination r...
Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma [0.03%]
少即是安全和有效吗？多发性骨髓瘤自体移植后不同马法兰剂量的预后分析
Sumeet Mirgh,Arti Goel,Sachin Punatar et al.
Sumeet Mirgh et al.
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience [0.03%]
中枢神经系统受侵的里特尔综合征(RTS)患者临床特点及预后分析：梅奥诊所的经验
Domitilla Baccon,Suheil Albert Atallah-Yunes,Paul J Hampel et al.
Domitilla Baccon et al.
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia [0.03%]
异柠檬酸脱氢酶1基因突变通过下调IL1R1驱动急性髓系白血病中炎症反应失调
Sophie Steinhäuser,Thomas Beder,Emely Hübner et al.
Sophie Steinhäuser et al.
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma [0.03%]
复发难治多发性骨髓瘤患者外周血免疫细胞图谱和BCMA CAR-T治疗的反应
Toshali Pandey,Bhavesh Mohan Lal,Jawad Alrawabdeh et al.
Toshali Pandey et al.
Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms [0.03%]
年轻和家族性骨髓增殖性肿瘤中频繁出现的临床相关生殖系DNA修复基因变异
Robert Meyer,Maria Jimena Rodriguez,Madeline Caduc et al.
Robert Meyer et al.
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data [0.03%]
FLT3共突变在不同分子亚型的重型急性髓系白血病中的预后价值：基于真实世界基因组数据的分析
Yu-Sung Chang,Feng-Ming Tien,Yu-Wen Wang et al.
Yu-Sung Chang et al.